miRNAs

2

Review clinical trials related to miRNAs. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Microgreens and miRNAs

In this study, we investigated the impact of a comprehensive microgreen and wheatgrass juice protocol on the miRNA response following a standardized EIMD model and whether microgreen consumption could modulate key miRNA markers of neuromuscular regeneration and metabolic adaptation, thereby offering a novel nutritional approach to enhancing holistic recovery in athletes.

Participants needed: 15
Trial details
Age: 19-24Biological sex: MaleType: InterventionalSponsor: Çanakkale Onsekiz Mart UniversityUpdated: Apr 20, 2026
Eligibility criteria

Not listed

Status: Recruiting

PTEN and Organ-Specific microRNAs in Metastatic Breast Cancer

This prospective observational study aims to evaluate serum levels of PTEN, a tumor suppressor gene, and organ-specific microRNAs (miRNAs) associated with metastatic patterns in breast cancer. Serum samples will be analyzed using quantitative reverse transcription polymerase chain reaction (qRT-PCR)-based miRNA profiling and enzyme-linked immunosorbent assay (ELISA)-based PTEN quantification. Three groups will be included: patients with metastatic breast cancer (n=80), patients with non-metastatic early-stage breast cancer (n=40), and healthy controls (n=40). The primary objective is to identify serum biomarkers that differentiate metastatic from non-metastatic disease. Secondary analyses will evaluate correlations between biomarker levels and organ-specific metastatic involvement, including bone, lung, liver, and brain metastases. Findings from this study may support the development of a noninvasive serum-based tool for predicting metastatic patterns in breast cancer.

Participants needed: 160
Trial details
Age: 18+Biological sex: FemaleType: ObservationalSponsor: Atlas UniversityUpdated: Jan 27, 2026Locations: 1
Eligibility criteria

Female individuals aged ≥18 years [+4]

History of any other primary malignancy [+6]